Press Releases
Investor Resources
Press Releases
Press Release
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of PericarditisFebruary 15, 2024
Press Release
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital MarketJanuary 24, 2024
Press Release
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute MyocarditisJanuary 9, 2024
Press Release
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementOctober 20, 2023